[go: up one dir, main page]

WO2011126342A3 - Novel use of polygonatum falcatum or polygonatum sibiricum extract - Google Patents

Novel use of polygonatum falcatum or polygonatum sibiricum extract Download PDF

Info

Publication number
WO2011126342A3
WO2011126342A3 PCT/KR2011/002491 KR2011002491W WO2011126342A3 WO 2011126342 A3 WO2011126342 A3 WO 2011126342A3 KR 2011002491 W KR2011002491 W KR 2011002491W WO 2011126342 A3 WO2011126342 A3 WO 2011126342A3
Authority
WO
WIPO (PCT)
Prior art keywords
polygonatum
obesity
falcatum
metabolic syndrome
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/002491
Other languages
French (fr)
Korean (ko)
Other versions
WO2011126342A2 (en
Inventor
권혁상
고종희
유종수
윤종민
장현수
연승우
강재훈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ildong Pharmaceutical Co Ltd
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Priority to CN2011800175142A priority Critical patent/CN102844042A/en
Priority to JP2013503700A priority patent/JP5799082B2/en
Publication of WO2011126342A2 publication Critical patent/WO2011126342A2/en
Publication of WO2011126342A3 publication Critical patent/WO2011126342A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel use of a Polygonatum falcatum or Polygonatum sibiricum extract for preventing and treating obesity or metabolic syndrome, and more specifically, to a pharmaceutical or food composition containing a Polygonatum falcatum or Polygonatum sibiricum extract for preventing and treating obesity, obesity complications or metabolic syndrome, a novel use of a Polygonatum falcatum or Polygonatum sibiricum extract for preparation of a medicine for preventing and treating obesity, obesity complications or metabolic syndrome, and a method for treating obesity, obesity complications or metabolic syndrome by using the extract. The Polygonatum falcatum or Polygonatum sibiricum extract suppresses differentiation of fat cells and maintains SIRT1 at a high level, thereby reducing body weight, abdominal fat and glucose tolerance, and thus can be helpfully used to prevent and treat obesity, obesity complications or metabolic syndrome.
PCT/KR2011/002491 2010-04-09 2011-04-08 Novel use of polygonatum falcatum or polygonatum sibiricum extract Ceased WO2011126342A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2011800175142A CN102844042A (en) 2010-04-09 2011-04-08 Novel use of polygonatum falcatum or polygonatum sibiricum extract
JP2013503700A JP5799082B2 (en) 2010-04-09 2011-04-08 用途 New use of yellow or yellow extract

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100032921 2010-04-09
KR10-2010-0032921 2010-04-09
KR1020100095987A KR101018531B1 (en) 2010-04-09 2010-10-01 Composition for the prevention and treatment of obesity or metabolic syndrome comprising the extract of perilla leaf or layered hook
KR10-2010-0095987 2010-10-01

Publications (2)

Publication Number Publication Date
WO2011126342A2 WO2011126342A2 (en) 2011-10-13
WO2011126342A3 true WO2011126342A3 (en) 2012-03-08

Family

ID=43938249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002491 Ceased WO2011126342A2 (en) 2010-04-09 2011-04-08 Novel use of polygonatum falcatum or polygonatum sibiricum extract

Country Status (4)

Country Link
JP (1) JP5799082B2 (en)
KR (1) KR101018531B1 (en)
CN (1) CN102844042A (en)
WO (1) WO2011126342A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134125B2 (en) * 2011-11-18 2017-05-24 株式会社紀文食品 Reverse transcriptase inhibitors and kits
CN104324228B (en) * 2014-11-26 2017-09-29 安徽省旌德博仕达农业科技有限公司 A kind of sealwort lozenge and preparation method thereof
CN110537467A (en) * 2019-09-25 2019-12-06 贵州百灵企业集团制药股份有限公司 A kind of method for raising seedlings of Polygonatum yunnanensis seeds in greenhouse
WO2022075059A1 (en) * 2020-10-07 2022-04-14 株式会社 資生堂 Sirtuin 1 activator
CN112870305A (en) * 2021-02-26 2021-06-01 云南彝风堂医疗科技有限公司 Pharmaceutical composition and preparation for treating gout, and preparation method and application thereof
CN115707782A (en) * 2022-08-10 2023-02-21 贵州省植物园（贵州省园林科学研究所、贵州省植物研究所） Method for screening polygonatum cyrtonema pathogenic fungi

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020030687A (en) * 2000-10-19 2002-04-25 신동수 Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities
KR20020033336A (en) * 2000-10-30 2002-05-06 박선민 Food composition comprising extract from Polygonatum odoratum (Mill.) Druce
KR20070059395A (en) * 2005-12-06 2007-06-12 대구한의대학교산학협력단 Immunity-enhancing Pharmaceutic Compositions Containing Citrine Extract as an Active Ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241293A (en) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd Maillard reaction inhibitor
CN1939475A (en) * 2006-09-21 2007-04-04 张志祥 Fructus lycii kudzuvine root capsule sand production thereof
CN101352539A (en) * 2008-09-05 2009-01-28 何进爱 Composite of Chinese traditional medicine for diabetes mellitus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020030687A (en) * 2000-10-19 2002-04-25 신동수 Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities
KR20020033336A (en) * 2000-10-30 2002-05-06 박선민 Food composition comprising extract from Polygonatum odoratum (Mill.) Druce
KR20070059395A (en) * 2005-12-06 2007-06-12 대구한의대학교산학협력단 Immunity-enhancing Pharmaceutic Compositions Containing Citrine Extract as an Active Ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONGBIN CHEN ET AL.: "Hypoglycemic effects of aqueous extract of Rhizoma Polygonati Odorati in mice and rats", JOURNAL OF ETHNOPHARMACOLOGY, vol. 74, 2001, pages 225 - 229 *
S. B. CHOI ET AL.: "The Effects of Water Extract ofPolygonatum Odoratum (Mill) Druce on Insulin Resistance in 90% Pancreatectomized Rats", JOURNAL OF FOOD SCIENCE, vol. 67, no. 6, 2002, pages 2375 - 2379 *

Also Published As

Publication number Publication date
CN102844042A (en) 2012-12-26
JP5799082B2 (en) 2015-10-21
KR101018531B1 (en) 2011-03-11
JP2013523810A (en) 2013-06-17
WO2011126342A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2008143182A1 (en) Composition containing licorice-derived polyphenol
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
WO2011126342A3 (en) Novel use of polygonatum falcatum or polygonatum sibiricum extract
WO2010146568A3 (en) Bifidobacteria for treating diabetes and related conditions
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2012033792A3 (en) Treatment of diseases
WO2018169282A3 (en) Pharmaceutical composition containing atpif1 for treatment of diabetes
WO2018093238A3 (en) Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity
HRP20240115T1 (en) Increasing drug bioavailability in naltrexone therapy
BR112012013011A2 (en) odt; odt composition; method for preparing a multiparticulate odt tablet, method for treating or preventing postoperative nausea and vomiting or post-discharge nausea and vomiting for up to 24 hours after dosing, method for treating pu preventing nausea for up to 24 hours after dosing and Method for treating or preventing nausea and vomiting associated with radiotherapy in patients receiving either full body irradiation, single high dose to the abdomen, or daily fractions to the abdomen for up to 24 hours after dosing.
WO2012024583A3 (en) Oxysterol compounds
JP2011504921A5 (en)
WO2014102776A3 (en) Process for the large scale production of fruit cells and treatment of diseases with such cells
WO2011019735A3 (en) Nutritional supplements
WO2012064159A3 (en) Anticancer composition
JP2017538693A5 (en)
WO2018093237A3 (en) Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity
WO2016008642A3 (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
Sulaberidze et al. Dietary fiber's benefit for gallstone disease prevention during rapid weight loss in obese patients
WO2012105816A3 (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
WO2012091425A3 (en) Composition containing a 4-hydroxytamoxifen analog or the pharmaceutically acceptable salts thereof as an active ingredient for preventing or treating diseases associated with metabolic syndrome
WO2012154009A3 (en) Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
WO2011062458A3 (en) Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180017514.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766193

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2013503700

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766193

Country of ref document: EP

Kind code of ref document: A2